Daily Highlights

Wednesday, September 8 3 Total

High-Risk MDS: Where We Are and Where We Are Heading

Drs. Garcia-Manero and Sallman discuss current challenges and future directions in higher-risk MDS.

Lower-Risk MDS: Where We Are and Where We Are Heading

Drs. Garcia-Manero and Sallman discuss potential paradigm-shifting strategies for lower-risk MDS.

Evolution of Novel Therapies in the Treatment of Acute Lymphoblastic Leukemia

Drs. Jabbour and Shah discuss the exciting advances that are changing the therapeutic landscape of ALL.

Recent Updates in the Treatment of Myeloproliferative Neoplasms

MPN Therapies in Practice: Drs. Verstovsek and Michaelis discuss emerging data for patients with ET, PV, and MF.

Hot Topics in Chronic Lymphocytic Leukemia

CLL: Drs. Wierda and O’Brien discuss recent progress and shifting standards of care.

Recent Developments and Progress in Chronic Myeloid Leukemia

CML: Drs. Cortes and Pemmaraju discuss developments and progress in 2021 and beyond.

$CAR-T vs. Bispecific Agents in the Treatment of Refractory Multiple Myeloma$

CAR-T vs. Bispecific Agents in the Treatment of Refractory Multiple Myeloma

What’s next for myeloma? Drs. Lonial and Usmani weigh the pros and cons of BCMA-targeted therapies.

MRD Directed Therapeutic Decision Making in Multiple Myeloma

How useful is MRD? Drs. Lonial and Usmani highlight the potential benefits and drawbacks in MM management.

Emerging Strategies in the Treatment of Hodgkin Lymphoma

Hodgkin Lymphoma: Drs. Ansell and Moskowitz discuss evolving treatment approaches in HL.

New and Emerging Agents in the Treatment of Diffuse Large B-Cell Lymphoma

Aggressive B-Cell Lymphoma: Drs. Sehn and Salles discuss emerging data and future directions in DLBCL.

Hot Topics in Indolent Lymphoma

Indolent B-cell Lymphoma: Drs. Nastoupil and Martin discuss recent advances and challenges in the treatment of patients with indolent B-cell lymphomas.

Exciting Advances and Unanswered Questions with CAR T-Cell Therapy

What’s new in cellular therapy? Drs. Maus and Locke highlight ongoing developments and look toward the future.

Exciting Aspects in AML Therapies in 2021 and Beyond

AML: Drs. Daver and Wang discuss emerging agents and combinations, including immunotherapy and targeted agents.